The At its November 2022 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines for Human Use (EMA) Extension of approval for Durvalumab (Imfinzi, AstraZeneca) recommended:
The PDL-1 inhibitor is also indicated in combination with gemcitabine and cisplatin for the first-line treatment of adults with unresectable or metastatic bile duct cancer (BTC).
So far, the immunotherapeutic agent has been used in lung cancer (NSCLC and ES-SCLC).
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassungserweiterung-f%25C3%25BCr-durvalumab-2022a1002753
Comments are closed.